Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres

Cancer Letters

Volumn 296, Issue 2, 2010, Pages 168-177

  Mihaliak, Alicia M ^a   Gilbert, Candace A ^a   Li, Li ^a   Daou, Marie Claire ^a   Moser, Richard P ^a   Reeves, Andrew ^b   Cochran, Brent H ^b   Ross, Alonzo H ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BCNU; Cancer stem cells; Chemotherapy; DNA damage; Glioblastoma; Neurosphere; Temozolomide

Indexed keywords

CARMUSTINE; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; CELL ADHESION; CELL CULTURE TECHNIQUES; CELL DEATH; CELL DIVISION; CELL LINE, TUMOR; DACARBAZINE; DNA PRIMERS; DNA, COMPLEMENTARY; EXONS; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 77955275305     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.04.005     Document Type: Article

References (50)

1. Friedman H.S., Kerby T., Calvert H. Temozolomide and treatment of malignant glioma. Clin. Cancer. Res. 2000, 6:2585-2597.
2. Grossman S.A., Reinhard C., Colvin O.M., Chasin M., Brundrett R., Tamargo R.J., Brem H. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J. Neurosurg. 1992, 76:640-647.
3. Sarkaria J.N., Kitange G.J., James C.D., Plummer R., Calvert H., Weller M., Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer. Res. 2008, 14:2900-2908.
4. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet. Oncol. 2009, 10:2960-2965.
5. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
6. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
7. Hambardzumyan D., Becher O.J., Rosenblum M.K., Pandolfi P.P., Manova-Todorova K., Holland E.C. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008, 22:436-448.
8. Rietze R.L., Valcanis H., Brooker G.F., Thomas T., Voss A.K., Bartlett P.F. Purification of a pluripotent neural stem cell from the adult mouse brain. Nature 2001, 412:736-739.
9. Reynolds B.A., Weiss S. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev. Biol. 1996, 175:1-13.
10. Gritti A., Parati E.A., Cova L., Frolichsthal P., Galli R., Wanke E., Faravelli L., Morassutti D.J., Roisen F., Nickel D.D., Vescovi A.L. Multipotential stem cells from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor. J. Neurosci. 1996, 16:1091-1100.
11. Gal H., Makovitzki A., Amariglio N., Rechavi G., Ram Z., Givol D. A rapid assay for drug sensitivity of glioblastoma stem cells. Biochem. Biophys. Res. Commun. 2007, 358:908-913.
12. Clarke M.F. A self-renewal assay for cancer stem cells. Cancer Chemother. Pharmacol. 2005, 56:64-68.
13. Reynolds B.A., Rietze R.L. Neural stem cells and neurospheres - re-evaluating the relationship. Nat. Methods 2005, 2:333-336.
14. Golmohammadi M.G., Blackmore D.G., Large B., Azari H., Esfandiary E., Paxinos G., Franklin K.B., Reynolds B.A., Rietze R.L. Comparative analysis of the frequency and distribution of stem and progenitor cells in the adult mouse brain. Stem Cells 2008, 26:979-987.
15. Louis S.A., Rietze R.L., Deleyrolle L., Wagey R.E., Thomas T.E., Eaves A.C., Reynolds B.A. Enumeration of neural stem and progenitor cells in the neural colony-forming cell assay. Stem Cells 2008, 26:988-996.
16. Friedrich J., Seidel C., Ebner R., Kunz-Schughart L.A. Spheroid-based drug screen: considerations and practical approach. Nat. Protoc. 2009, 4:309-324.
17. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., Pastorino S., Purow B.W., Christopher N., Zhang W., Park J.K., Fine H.A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403.
18. Mellor H.R., Ferguson D.J., Callaghan R. A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br. J. Cancer 2005, 93:302-309.
19. Viale A., De Franco F., Orleth A., Cambiaghi V., Giuliani V., Bossi D., Ronchini C., Ronzoni S., Muradore I., Monestiroli S., Gobbi A., Alcalay M., Minucci S., Pelicci P.G. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009, 457:51-56.
20. Chauffert B., Dimanche-Boitrel M.T., Garrido C., Ivarsson M., Martin M., Martin F., Solary E. New insights into the kinetic resistance to anticancer agents. Cytotechnology 1998, 27:225-235.
21. Ishikawa F., Yoshida S., Saito Y., Hijikata A., Kitamura H., Tanaka S., Nakamura R., Tanaka T., Tomiyama H., Saito N., Fukata M., Miyamoto T., Lyons B., Ohshima K., Uchida N., Taniguchi S., Ohara O., Akashi K., Harada M., Shultz L.D. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 2007, 25:1315-1321.
22. Reynolds B.A., Tetzlaff W., Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J. Neurosci. 1992, 12:4565-4574.
23. Li L., Dutra A., Pak E., Labrie J.E., Gerstein R.M., Pandolfi P.P., Recht L.D., Ross A.H. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro-oncology 2009, 11:9-21.
24. Zhang X., Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998, 92:3829-3840.
25. Sen A., Kallos M.S., Behie L.A. New tissue dissociation protocol for scaled-up production of neural stem cells in suspension bioreactors. Tissue Eng. 2004, 10:904-913.
26. Sherry M.M., Reeves A., Wu J.K., Cochran B.H. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009, 27:2383-2392.
27. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
28. Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.C., Van Meir E.G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999, 9:469-479.
29. Collins A.R., Oscoz A.A., Brunborg G., Gaivao I., Giovannelli L., Kruszewski M., Smith C.C., Stetina R. The comet assay: topical issues. Mutagenesis 2008, 23:143-151.
30. Ueda-Kawamitsu H., Lawson T.A., Gwilt P.R. In vitro pharmacokinetics and pharmacodynamics of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem. Pharmacol. 2002, 63:1209-1218.
31. Gunther W., Pawlak E., Damasceno R., Arnold H., Terzis A.J. Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br. J. Cancer 2003, 88:463-469.
32. Tchoghandjian A., Baeza N., Colin C., Cayre M., Metellus P., Beclin C., Ouafik L., Figarella-Branger D. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol XXX 2009, XXX.
33. Mao X.G., Zhang X., Xue X.Y., Guo G., Wang P., Zhang W., Fei Z., Zhen H.N., You S.W., Yang H. Brain tumor stem-like cells identified by neural stem cell marker CD15. Transl. Oncol. 2009, 2:247-257.
34. Ogden A.T., Waziri A.E., Lochhead R.A., Fusco D., Lopez K., Ellis J.A., Kang J., Assanah M., McKhann G.M., Sisti M.B., McCormick P.C., Canoll P., Bruce J.N. Identification of A2B5+CD133-tumor-initiating cells in adult human gliomas. Neurosurgery 2008, 62:505-514. Discussion 514-505.
35. Sun Y., Kong W., Falk A., Hu J., Zhou L., Pollard S., Smith A. CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. PLoS ONE 2009, 4:e5498.
36. Son M.J., Woolard K., Nam D.H., Lee J., Fine H.A. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009, 4:440-452.
37. Calabrese E.J. Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses. Crit. Rev. Toxicol. 2005, 35:463-582.
38. Gilbert C.A., Ross A.H. Cancer stem cells: cell culture, markers, and targets for new therapies. J. Cell. Biochem. 2009, 108:1031-1038.
39. Wang J., Sakariassen P.O., Tsinkalovsky O., Immervoll H., Boe S.O., Svendsen A., Prestegarden L., Rosland G., Thorsen F., Stuhr L., Molven A., Bjerkvig R., Enger P.O. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer 2008, 122:761-768.
40. Cheng J.X., Liu B.L., Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors?. Cancer Treat. Rev. 2009, 35:403-408.
41. Dittfeld C., Dietrich A., Peickert S., Hering S., Baumann M., Grade M., Ried T., Kunz-Schughart L.A. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. Radiother. Oncol. 2009, 92:353-361.
42. 6-methylguanine. Oncogene 2007, 26:186-197.
43. Batista L.F., Roos W.P., Christmann M., Menck C.F., Kaina B. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res. 2007, 67:11886-11895.
44. Chakravarti A., Dicker A., Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:927-931.
45. Nagane M., Levitzki A., Gazit A., Cavenee W.K., Huang H.J. Drug resistance of human glioblastoma cells conferred by a tumor- specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. USA 1998, 95:5724-5729.
46. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 1999, 13:2905-2927.
47. Fung L.K., Ewend M.G., Sills A., Sipos E.P., Thompson R., Watts M., Colvin O.M., Brem H., Saltzman W.M. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. 1998, 58:672-684.
48. Baker S.D., Wirth M., Statkevich P., Reidenberg P., Alton K., Sartorius S.E., Dugan M., Cutler D., Batra V., Grochow L.B., Donehower R.C., Rowinsky E.K. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res. 1999, 5:309-317.
49. Spiro T.P., Liu L., Majka S., Haaga J., Willson J.K., Gerson S.L. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin. Cancer Res. 2001, 7:2309-2317.
50. Ostermann S., Csajka C., Buclin T., Leyvraz S., Lejeune F., Decosterd L.A., Stupp R. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res. 2004, 10:3728-3736.